8-K
filed June 15, 2026, 9:14 AM ET
ticker ENGN
CIK 0001980845
other material
confidence high
sentiment negative
materiality 0.85
enGene Therapeutics Inc. (ENGN): restructuring charge — enGene cuts workforce ~50%, CMO and CFO resign; Q2 loss widens to $30.2M
enGene Therapeutics Inc.
- Workforce reduction of ~50% to streamline ops and preserve cash; restructuring costs est. $5.7-$6.4M cash plus $4.7-$5.0M non-cash stock comp.
- CFO Ryan Daws to depart July 15, 2026; Kathleen Richton appointed SVP Finance and principal financial officer.
- CMO Dr. Hussein Sweiti resigned effective June 14; Dr. William Grossman named interim CMO.
- Q2 net loss $30.2M ($0.43/share) vs $25.8M ($0.51/share) YoY; cash, equivalents and marketable securities $285.2M.
- LEGEND Cohort 1: 54% CR at any time; awaiting 12-month durability data; BLA filing and FDA meeting planned for 2H 2026.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
enGene Therapeutics Inc. reported financial results for the second quarter ended April 30, 2026.
- Period
- the second quarter ended April 30, 2026
- Result
- reported results
Exact text from the filing
enGene Therapeutics Inc. (the “Company”) announced its financial results for the three months ended April 30, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Hussein Sweiti resigned as Chief Medical Officer at enGene Therapeutics Inc..
- Action
- resigned
- Role
- Chief Medical Officer
Exact text from the filing
On June 13, 2026, Dr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kathleen Richton was appointed as Senior Vice President, Finance at enGene Therapeutics Inc..
- Action
- appointed
- Role
- Senior Vice President, Finance
Exact text from the filing
the Board appointed Kathleen Richton as Senior Vice President, Finance of the Company, with her appointment to become effective on or about July 16, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ryan Daws departed as Chief Financial Officer at enGene Therapeutics Inc..
- Action
- depart
- Role
- Chief Financial Officer
Exact text from the filing
the Company announced that its Chief Financial Officer, Ryan Daws, will depart the Company effective July 15, 2026
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million affecting the Company (approximately 50%).
- Type
- restructuring
- Charge
- approximately $5.7 to $6.4 million
- Affected area
- the Company
- Headcount
- approximately 50%
Exact text from the filing
activities required to support the commercial launch of detalimogene in 2027, if approved. The Company currently estimates it will incur restructuring costs of approximately $5.7 to $6.4 million, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash stock-based
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.